Loncastuximab tesirine plus rituximab in patients with R/R FL

Patients with R/R FL may have rapid disease progression, characterized by increasingly treatment-refractory disease and shorter intervals to next therapy. There remains an unmet need for fixed-duration novel agents that can achieve high response rates and durable efficacy whilst maintaining acceptable safety profiles.¹

A single arm phase II trial (NCT04998669) conducted at the Sylvester Comprehensive Cancer Center, US, evaluated the efficacy and safety of loncastuximab tesirine plus rituximab in patients with R/R FL (N = 39).¹ Patients who had progressed after ≥2 lines of systemic therapy and presenting with progression or relapse within 24 months (POD24) after 1L treatment, ≥1 GELF criteria, or second relapse, had measurable disease according to Lugano 2014 classification, and ECOG PS 0–2 were included. The primary endpoint was CR at Week 12 assessed by the Lugano 2014 classification, with a secondary endpoint of Week 12 ORR. Results were published in Lancet Haematology by Alderuccio et al.¹